ADVERSE REACTIONS SECTION.

6 ADVERSE REACTIONS. The following serious adverse reactions are described elsewhere in the labeling:Secondary Malignancy and Leukemia [see Warnings and Precautions 5.1)] Veno-occlusive Disease [see Warnings and Precautions 5.2)] Extravasation [see Warnings and Precautions 5.3)] Myelosuppression [see Warnings and Precautions 5.4)] Immunizations [see Warning and Precautions 5.5)] Severe Mucocutaneous Reactions [see Warnings and Precautions 5.6)] Renal Toxicity [see Warnings and Precautions 5.7)] Hepatotoxicity [see Warnings and Precautions 5.8)] Potentiation of Radiation Toxicity and Radiation Recall [see Warnings and Precautions 5.9)] Common adverse reactions are: infection, alopecia, rash, dysphagia, fatigue, fever, nausea, vomiting, anemia, neutropenia, thrombocytopenia, mucositis, and hepatotoxicity.The following adverse reactions have been identified in clinical studies or postmarketing reports. Because some of these reactions were reported voluntarily from population of uncertain size, it is not always possible to reliably estimate their frequency or establish causal relationship to drug exposure.Infections: infections including sepsis with fatal outcome Hematologic: anemia, leukopenia, thrombocytopenia, pancytopenia, reticulocytopenia, neutropenia, febrile neutropenia, disseminated intravascular coagulation Immune system: hypersensitivity Metabolism and nutrition: anorexia, hypocalcemia, tumor lysis syndrome Nervous system: peripheral neuropathy Ocular: optic neuropathy Vascular: thrombophlebitis, hemorrhage Respiratory, thoracic and mediastinal: pneumonitis, pneumothorax Gastrointestinal: nausea, vomiting, abdominal pain, diarrhea, constipation, gastrointestinal ulceration, cheilitis, dysphagia, esophagitis, ulcerative stomatitis, ascites, proctitis, mucositis Hepatobiliary: liver function test abnormalities, hepatomegaly, hepatitis, hepatic failure with reports of death, hepatic veno-occlusive disease Dermatologic: alopecia, rash, dermatitis, acne, erythema multiforme, Stevens Johnson Syndrome, radiation recall, toxic epidermal necrolysis Musculoskeletal and connective tissue: myalgia, growth retardation Renal and urinary: renal impairment, renal failure General: fatigue, fever, malaise Secondary Malignancy and Leukemia [see Warnings and Precautions 5.1)] Veno-occlusive Disease [see Warnings and Precautions 5.2)] Extravasation [see Warnings and Precautions 5.3)] Myelosuppression [see Warnings and Precautions 5.4)] Immunizations [see Warning and Precautions 5.5)] Severe Mucocutaneous Reactions [see Warnings and Precautions 5.6)] Renal Toxicity [see Warnings and Precautions 5.7)] Hepatotoxicity [see Warnings and Precautions 5.8)] Potentiation of Radiation Toxicity and Radiation Recall [see Warnings and Precautions 5.9)] Common adverse reactions are: infection, alopecia, rash, dysphagia, fatigue, fever, nausea, vomiting, anemia, neutropenia, thrombocytopenia, mucositis, and hepatotoxicity. 6) To report SUSPECTED ADVERSE REACTIONS, contact Recordati Rare Diseases at 1-800-575-8374 or FDA at 1-800-FDA-1088 orwww.fda.gov/medwatch.

DOSAGE & ADMINISTRATION SECTION.

2 DOSAGE AND ADMINISTRATION. Wilms Tumor: The recommended dose is 45 mcg/kg intravenously once every to weeks for up to 26 weeks, as part of multi-agent combination chemotherapy regimen. 2.1) Rhabdomyosarcoma: The recommended dose is 15 mcg/kg intravenously once daily for days every to weeks for up to 112 weeks, as part of multi-agent combination chemotherapy regimen. 2.2) Ewing Sarcoma: The recommended dose is 1250 mcg/m intravenously once every weeks for 51 weeks, as part of multi-agent combination chemotherapy regimen. 2.3) Metastatic Nonseminomatous Testicular Cancer: The recommended dose is 1000 mcg/m intravenously every weeks, as part of cisplatin-based, multi-drug chemotherapy regimen. 2.4) Gestational Trophoblastic Neoplasia:Non-metastatic and Low-risk Metastatic Disease: The recommended dose is 12 mcg/kg intravenously daily for days, as single agent. 2.5) High-risk Metastatic Disease: The recommended dose is 500 mcg intravenously on Days and every weeks for up to weeks, as part of multi-agent combination chemotherapy regimen. 2.5) Regional Perfusion in Locally Recurrent and Locoregional Solid Malignancies:Lower Extremity or Pelvis: The recommend dose is 50 mcg/kg once with melphalan. 2.6) Upper Extremity: The recommended dose is 35 mcg/kg once with melphalan. 2.6) Wilms Tumor: The recommended dose is 45 mcg/kg intravenously once every to weeks for up to 26 weeks, as part of multi-agent combination chemotherapy regimen. 2.1) Rhabdomyosarcoma: The recommended dose is 15 mcg/kg intravenously once daily for days every to weeks for up to 112 weeks, as part of multi-agent combination chemotherapy regimen. 2.2) Ewing Sarcoma: The recommended dose is 1250 mcg/m intravenously once every weeks for 51 weeks, as part of multi-agent combination chemotherapy regimen. 2.3) Metastatic Nonseminomatous Testicular Cancer: The recommended dose is 1000 mcg/m intravenously every weeks, as part of cisplatin-based, multi-drug chemotherapy regimen. 2.4) Gestational Trophoblastic Neoplasia:. Non-metastatic and Low-risk Metastatic Disease: The recommended dose is 12 mcg/kg intravenously daily for days, as single agent. 2.5) High-risk Metastatic Disease: The recommended dose is 500 mcg intravenously on Days and every weeks for up to weeks, as part of multi-agent combination chemotherapy regimen. 2.5) Regional Perfusion in Locally Recurrent and Locoregional Solid Malignancies:. Lower Extremity or Pelvis: The recommend dose is 50 mcg/kg once with melphalan. 2.6) Upper Extremity: The recommended dose is 35 mcg/kg once with melphalan. 2.6) 2.1 Recommended Dosage for Wilms Tumor. The recommended dose of Dactinomycin, as part of multi-agent combination chemotherapy regimen, is 45 mcg/kg intravenously once every to weeks for up to 26 weeks.. 2.2 Recommended Dosage for Rhabdomyosarcoma. The recommended dose of Dactinomycin, as part of multi-agent combination chemotherapy regimen, is 15 mcg/kg intravenously once daily for days every to weeks for up to 112 weeks.. 2.3 Recommended Dosage for Ewing Sarcoma. The recommended dose of Dactinomycin for injection, as part of multi-agent combination chemotherapy regimen, is 1250 mcg/m intravenously once every weeks for 51 weeks. 2.4 Recommended Dosage for Metastatic Nonseminomatous Testicular Cancer. The recommended dose of Dactinomycin for injection, as part of cisplatin-based, multi-agent combination chemotherapy regimen, is 1000 mcg/m intravenously once every weeks for 12 weeks. 2.5 Recommended Dosage for Gestational Trophoblastic Neoplasia. The recommended dose of Dactinomycin for injection for nonmetastatic and low-risk metastatic disease is 12 mcg/kg intravenously daily for five days as single agent.The recommended dose of Dactinomycin for injection, as part of multi-agent combination chemotherapy regimen, for high-risk metastatic disease is 500 mcg intravenously on Days and every weeks for up to weeks.. 2.6 Recommended Dosage for Regional Perfusion in Locally Recurrent and Locoregional Solid Malignancies. The recommended dose of Dactinomycin, in combination with melphalan, is 50 mcg/kg once for lower extremity or pelvis.The recommended dose of Dactinomycin, in combination with melphalan, is 35 mcg/kg once for upper extremity.Calculate the dose for obese or edematous patients based on ideal body weight. 2.7 Preparation and Administration. Dactinomycin is cytotoxic drug. Follow applicable special handling and disposal procedures. Visually inspect the vials for particulate matter and discoloration, whenever solution and container permit.PreparationReconstitute each vial by adding 1.1 mL of Sterile Water for Injection without preservative using aseptic techniques.The reconstituted product should be clear, gold-colored solution at concentration of 500 mcg/mL.Further dilute the reconstituted product with 5% Dextrose Injection or 0.9% Sodium Chloride Injection to yield concentrations greater than 10 mcg/mL.Store at room temperature for no more than hours from reconstitution to completion of injection or infusion. Discard after hours.Dactinomycin does not contain preservative. Discard any unused portions.AdministrationAdminister the diluted reconstituted product intravenously over 10 to 15 minutes.Do not use in-line filters with cellulose ester membrane.Management of ExtravasationDiscontinue Dactinomycin for burning or stinging sensation or other evidence indicating perivenous infiltration or extravasation.Manage confirmed or suspected extravasation as follows:Terminate the injection or infusion immediately and restart in another vein.Intermittent application of ice to the site for 15 minutes times daily for days [see Warnings and Precautions 5.3) ]. Dactinomycin is cytotoxic drug. Follow applicable special handling and disposal procedures. . Visually inspect the vials for particulate matter and discoloration, whenever solution and container permit.. Reconstitute each vial by adding 1.1 mL of Sterile Water for Injection without preservative using aseptic techniques.. The reconstituted product should be clear, gold-colored solution at concentration of 500 mcg/mL.. Further dilute the reconstituted product with 5% Dextrose Injection or 0.9% Sodium Chloride Injection to yield concentrations greater than 10 mcg/mL.. Store at room temperature for no more than hours from reconstitution to completion of injection or infusion. Discard after hours.. Dactinomycin does not contain preservative. Discard any unused portions.. Administer the diluted reconstituted product intravenously over 10 to 15 minutes.. Do not use in-line filters with cellulose ester membrane.. Discontinue Dactinomycin for burning or stinging sensation or other evidence indicating perivenous infiltration or extravasation.. Manage confirmed or suspected extravasation as follows:. Terminate the injection or infusion immediately and restart in another vein.. Intermittent application of ice to the site for 15 minutes times daily for days [see Warnings and Precautions 5.3) ].

INDICATIONS & USAGE SECTION.

1 INDICATIONS AND USAGE. Dactinomycin is an actinomycin indicated for the treatment of:adult and pediatric patients with Wilms tumor, as part of multi-phase, combination chemotherapy regimen. 1.1) adult and pediatric patients with rhabdomyosarcoma, as part of multiphase, combination chemotherapy regimen. 1.2) adult and pediatric patients with Ewing sarcoma, as part of multi-phase, combination chemotherapy regimen. 1.3) adult and pediatric patients with metastatic, nonseminomatous testicular cancer, as part of multi-phase, combination chemotherapy regimen. 1.4) post-menarchal patients with gestational trophoblastic neoplasia, as single agent or as part of combination chemotherapy regimen. 1.5) adult patients with locally recurrent or locoregional solid malignancies, as component of palliative or adjunctive regional perfusion. 1.6) adult and pediatric patients with Wilms tumor, as part of multi-phase, combination chemotherapy regimen. 1.1) adult and pediatric patients with rhabdomyosarcoma, as part of multiphase, combination chemotherapy regimen. 1.2) adult and pediatric patients with Ewing sarcoma, as part of multi-phase, combination chemotherapy regimen. 1.3) adult and pediatric patients with metastatic, nonseminomatous testicular cancer, as part of multi-phase, combination chemotherapy regimen. 1.4) post-menarchal patients with gestational trophoblastic neoplasia, as single agent or as part of combination chemotherapy regimen. 1.5) adult patients with locally recurrent or locoregional solid malignancies, as component of palliative or adjunctive regional perfusion. 1.6) 1.1 Wilms Tumor. Dactinomycin is indicated for the treatment of adult and pediatric patients with Wilms tumor, as part of multi-phase, combination chemotherapy regimen.. 1.2 Rhabdomyosarcoma. Dactinomycin is indicated for the treatment of adult and pediatric patients with rhabdomyosarcoma, as part of multi-phase, combination chemotherapy regimen.. 1.3 Ewing Sarcoma. Dactinomycin is indicated for the treatment of adult and pediatric patients with Ewing sarcoma, as part of multi-phase, combination chemotherapy regimen.. 1.4 Metastatic Nonseminomatous Testicular Cancer. Dactinomycin is indicated for the treatment of adult and pediatric patients with metastatic, nonseminomatous testicular cancer, as part of multi-phase, combination chemotherapy regimen.. 1.5 Gestational Trophoblastic Neoplasia. Dactinomycin is indicated for the treatment of post-menarchal patients with gestational trophoblastic neoplasia, as single agent or as part of combination chemotherapy regimen.. 1.6 Regional Perfusion in Locally Recurrent and Locoregional Solid Malignancies. Dactinomycin is indicated for the treatment of adult patients with locally recurrent or locoregional solid malignancies, as component of palliative or adjunctive regional perfusion.

PATIENT COUNSELING INFORMATION.

17 PATIENT COUNSELING INFORMATION. Secondary Malignancy or LeukemiaAdvise patients of the increased risk of secondary malignancies [see Warnings and Precautions 5.1)] Veno-occlusive DiseaseAdvise patients about the symptoms of VOD and to seek medical attention if they develop new onset jaundice, abdominal distention, or right upper quadrant pain [see Warnings and Precautions 5.2)] MyelosuppressionAdvise patients to contact their healthcare provider for any signs or symptoms of myelosuppression or infection [see Warnings and Precautions 5.4)] Severe Mucocutaneous ReactionsAdvise patients of the risk of severe mucocutaneous reactions and to contact their health care provided for new skin lesions, mouth sores or oropharyngeal lesions [see Warnings and Precautions 5.5)] Renal Toxicity or HepatotoxicityAdvise patients of the need for periodic laboratory testing to monitor for renal toxicity and hepatotoxicity [see Warnings and Precautions 5.7, 5.8)] Potentiation of Radiation Toxicity and Radiation RecallAdvise patients of the risk of increased radiation-induced gastrointestinal, myelosuppression and skin toxicity [see Warnings and Precautions 5.9)] Embryo-Fetal ToxicityAdvise females of reproductive potential of the potential risk to fetus. Advise females to inform their healthcare provider of known or suspected pregnancy [see Warnings and Precautions 5.10), Use in Specific Populations 8.1)] Advise females of reproductive potential to use effective contraception during treatment with Dactinomycin and for months after final dose [see Use in Specific Populations 8.3)] Advise male patients with female partners of reproductive potential to use effective contraception during treatment with Dactinomycin and for months after final dose [see Use in Specific Populations 8.3)] LactationAdvise females not to breastfeed during treatment with Dactinomycin and for 14 days after the final dose [see Use in Specific Populations 8.2)]. Manufactured by: Baxter Oncology GmbH, 33790 Halle/Westfalen, GermanyManufactured for: Prasco Laboratories, Mason, OH 45040 USARevised: August 2018APX1015/1. PRASCO.

USE IN SPECIFIC POPULATIONS SECTION.

8 USE IN SPECIFIC POPULATIONS. Lactation: Advise not to breastfeed. 8.2) See 17 for PATIENT COUNSELING INFORMATION.. 8.1 Pregnancy. Risk SummaryBased on findings from animal studies and its mechanism of action, Dactinomycin can cause fetal harm when administered to pregnant woman [see Clinical Pharmacology 12.1)] In animal reproduction studies, administration of dactinomycin to pregnant animals during the period of organogenesis was teratogenic, resulting in malformations at doses lower than the recommended human dose see Data). Advise pregnant women of the potential risk to fetus [see Use in Special Populations 8.3)] In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.DataAnimal DataDactinomycin was teratogenic in animals. Administration of dactinomycin to pregnant rats, rabbits, and hamsters during the period of organogenesis, increased the incidence of fetal malformations and caused embryotoxicity at doses (based on body surface area) as low as 0.2 times the clinical dose of 1250 mcg/m 2. 8.2 Lactation. Risk SummaryThere are no data on the presence of dactinomycin or its metabolites in human milk or their effects on the breastfed infant or on milk production. Because of the potential for serious adverse reactions in breastfed infants from Dactinomycin, advise women not to breastfeed during treatment with Dactinomycin and, based on limited published data regarding the dactinomycin half-life, for 14 days after the final dose.. 8.3 Females and Males of Reproductive Potential. Pregnancy TestingVerify the pregnancy status of females of reproductive potential prior to initiating Dactinomycin [see Use in Specific Population 8.1)]. ContraceptionDactinomycin can cause fetal harm when administered to pregnant woman [see Use in Specific Populations 8.1)]. FemalesAdvise females of reproductive potential to use effective contraception during treatment with Dactinomycin and for at least months after the final dose.MalesBecause of the potential for genotoxicity, advise males with female partners of reproductive potential to use effective contraception during treatment with Dactinomycin and for months after the final dose [see Nonclinical Toxicology 13.1)]. 8.4 Pediatric Use. The safety and effectiveness of dactinomycin have been established in pediatric patients with Wilms tumor, rhabdomyosarcoma, Ewing sarcoma, and metastatic nonseminomatous testicular cancer.The safety and effectiveness of dactinomycin have been established in post-menarchal pediatric patients with gestational trophoblastic neoplasia.The safety and effectiveness of Dactinomycin have not been established in pediatric patients undergoing regional perfusion for locally recurrent or locoregional solid malignancies.. 8.5 Geriatric Use. Clinical studies of Dactinomycin did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects.

WARNINGS AND PRECAUTIONS SECTION.

5 WARNINGS AND PRECAUTIONS. Secondary Malignancy or Leukemia: Increased risk of secondary malignancies following treatment. 5.1) Veno-occlusive Disease: Can cause severe or fatal VOD. Monitor for elevations in AST, ALT, total bilirubin, hepatomegaly, weight gain, or ascites. Consider delaying next dose. 5.2) Extravasation: Immediately interrupt the injection or infusion and apply ice. 2.7, 5.3) Myelosuppression: Monitor blood cell counts before each cycle. Delay next dose if severe myelosuppression has not improved. 5.4) Immunizations: Vaccination with live viral vaccines is not recommended before or during treatment. 5.5) Severe Mucocutaneous Reactions: Discontinue treatment 5.6) Renal Toxicity: Monitor creatinine and electrolytes frequently. 5.7) Hepatotoxicity: Monitor transaminases, alkaline phosphatase and bilirubin prior to and during treatment. 5.8) Potentiation of Radiation Toxicity and Radiation Recall: Reduce dose by 50% during concomitant radiation. Use caution when administering within two months of radiation. 5.9) Embryo-fetal Toxicity: Can cause fetal harm. Advise patients of the potential risk to fetus and to use effective contraception. 5.10, 8.1, 8.3) Secondary Malignancy or Leukemia: Increased risk of secondary malignancies following treatment. 5.1) Veno-occlusive Disease: Can cause severe or fatal VOD. Monitor for elevations in AST, ALT, total bilirubin, hepatomegaly, weight gain, or ascites. Consider delaying next dose. 5.2) Extravasation: Immediately interrupt the injection or infusion and apply ice. 2.7, 5.3) Myelosuppression: Monitor blood cell counts before each cycle. Delay next dose if severe myelosuppression has not improved. 5.4) Immunizations: Vaccination with live viral vaccines is not recommended before or during treatment. 5.5) Severe Mucocutaneous Reactions: Discontinue treatment 5.6) Renal Toxicity: Monitor creatinine and electrolytes frequently. 5.7) Hepatotoxicity: Monitor transaminases, alkaline phosphatase and bilirubin prior to and during treatment. 5.8) Potentiation of Radiation Toxicity and Radiation Recall: Reduce dose by 50% during concomitant radiation. Use caution when administering within two months of radiation. 5.9) Embryo-fetal Toxicity: Can cause fetal harm. Advise patients of the potential risk to fetus and to use effective contraception. 5.10, 8.1, 8.3) 5.1 Secondary Malignancy or Leukemia. The risk of developing secondary malignancies, including leukemia, is increased following treatment with Dactinomycin.. 5.2 Veno-occlusive Disease. Severe and fatal hepatic veno-occlusive disease (VOD) can occur with Dactinomycin. Risk factors for the development of VOD include age younger than years or concomitant radiotherapy. After treatment with Dactinomycin, monitor frequently for signs and symptoms of VOD; these include elevations in AST, ALT, total bilirubin, hepatomegaly, weight gain, or ascites. If patients develop VOD, considering delaying next dose of Dactinomycin. Resume, reduce dose or permanently discontinue based on severity of reaction and disease being treated.. 5.3 Extravasation. Extravasation of Dactinomycin can result in severe local tissue injury manifesting as blistering, ulcerations and persistent pain requiring wide excision surgery followed by split-thickness skin grafting. If any signs or symptoms of extravasation occur, immediately interrupt the injection or infusion. Apply ice to the site intermittently for 15 minutes, times day for days [see Dosage and Administration 2.7)] Observe closely and consult plastic surgery if necessary based on severity of reaction. 5.4 Myelosuppression. Severe and fatal myelosuppression, which may include neutropenia, thrombocytopenia and anemia, can occur with Dactinomycin. The nadir in neutrophil counts generally occurs 14 to 21 days after administration. Obtain complete blood counts prior to each treatment cycle. Delay next dose of Dactinomycin if severe myelosuppression has not improved. Consider dose reduction for patients with prolonged myelosuppression based on severity of reaction and disease being treated.. 5.5 Immunizations. The safety with live viral vaccines following Dactinomycin has not been studied and vaccination with live virus vaccines is not recommended before or during treatment.. 5.6 Severe Mucocutaneous Reactions. Severe mucocutaneous reactions, such as Steven-Johnson syndrome and Toxic Epidermal Necrolysis (TEN), can occur with Dactinomycin. Permanently discontinue Dactinomycin in patients who experience severe mucocutaneous reaction.. 5.7 Renal Toxicity. Abnormalities of renal function can occur with Dactinomycin. Monitor creatinine and electrolytes frequently during Dactinomycin therapy.. 5.8 Hepatotoxicity. Hepatotoxicity can occur with Dactinomycin. Monitor AST, ALT, alkaline phosphatase, and bilirubin prior to and during Dactinomycin therapy.. 5.9 Potentiation of Radiation Toxicity and Radiation Recall. Dactinomycin can increase radiation-induced gastrointestinal toxicity, myelosuppression, or erythema and vesiculation of the skin or buccal and pharyngeal mucosa. Reduce the dose of Dactinomycin by 50% during concomitant radiation.Radiation recall, affecting previously treated radiation fields, can occur in patients who receive Dactinomycin after prior radiation therapy. Although the risk can occur with distant radiation exposure, the risk appears highest when Dactinomycin is administered within two months of prior radiation.. 5.10 Embryo-Fetal Toxicity. Based on findings from animal studies and its mechanism of action, Dactinomycin can cause fetal harm when administered to pregnant woman. In animal reproduction studies, administration of dactinomycin to pregnant animals during the period of organogenesis was teratogenic, resulting in malformations at doses lower than the recommended human dose.Advise pregnant women of the potential risk to the fetus. Advise females of reproductive potential to use effective contraception during treatment with Dactinomycin and for at least months after the final dose. Advise males with female partners of reproductive potential to use effective contraception during treatment with Dactinomycin and for months after the final dose [see Use in Specific Populations 8.1, 8.3)].